Welcome to WordPress. This is your first post. Edit or delete it, then start writing!
Welcome to WordPress. This is your first post. Edit or delete it, then start writing!
NervGen Pharma Corp (“NervGen”) (TSXV: NGEN) (OTCQB: NGENF), is a clinical-stage biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury and other traumatic and neurologic disorders. NervGen’s lead candidate, NVG-291, is a first- and potential best-in-class candidate being evaluated in the Phase 1b/2a CONNECT SCI Study in individuals living with spinal cord injury.
Contact
112-970 Burrard Street
Unit 1290
Vancouver, BC V6Z 2R4
Phone: (778) 731-1711
Email: [email protected]
